Drug Profile
Research programme: cancer therapeutics - BridgeBio Pharma
Alternative Names: c-RAF degradation molecule - BridgeBio Pharma; KRAS inihibitor - BridgeBio Pharma; Pan-KRAS inhibitor - BridgeBio PharmaLatest Information Update: 02 Mar 2023
Price :
$50
*
At a glance
- Originator BridgeBio Pharma
- Class Antineoplastics; Small molecules
- Mechanism of Action KRAS protein inhibitors; Proto oncogene modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 23 Feb 2023 Preclinical trials in Cancer in USA (unspecified route) before February 2023 (BridgeBio Pharma pipeline, February 2023)
- 28 Mar 2022 No recent reports of development identified for research development in Cancer in USA
- 08 Feb 2018 KRAS inhibitor and c-Raf degradation molecule is available for licensing as of 08 Feb 2018. https://bridgebio.com/